Angel Chamorro1, Sergio Amaro2, Mar Castellanos3, Tomás Segura4, Juan Arenillas5, Joan Martí-Fábregas6, Jaime Gállego7, Jurek Krupinski8, Meritxell Gomis9, David Cánovas10, Xavier Carné11, Ramón Deulofeu12, Luis San Román13, Laura Oleaga14, Ferran Torres15, Anna M Planas16. 1. Comprehensive Stroke Center, Department of Neuroscience, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Spain; August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Electronic address: achamorro@clinic.ub.es. 2. Comprehensive Stroke Center, Department of Neuroscience, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Spain; August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. 3. Department of Neurology, Hospital Universitario Doctor Josep Trueta, Girona, Spain. 4. Department of Neurology, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. 5. Stroke Unit, Department of Neurology and Medicine, Hospital Clínico Universitario, Universidad de Valladolid, Valladolid, Spain. 6. Department of Neurology, Hospital de la Santa Creu i Sant Pau (IIb Sant Pau), Barcelona, Spain. 7. Department of Neurology, Hospital de Navarra, Pamplona, Spain. 8. Cerebrovascular Diseases Unit, Department of Neurology, University Hospital Mutua Terrassa, Terrassa, Barcelona, Spain. 9. Department of Neurosciences, Hospital Universitario Germans Trias i Pujol, Universidad Autónoma de Barcelona, Barcelona, Spain. 10. Neurology Service Corporació Sanitària Parc Taulí, Parc Taulí, Sabadell, Spain. 11. Department of Clinical Pharmacology, Unitat d'Avaluació, Suport i Prevenció, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Spain; August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. 12. Clinical Biochemistry Laboratory, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Spain. 13. Department of Radiology, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Spain. 14. Department of Radiology, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Spain; August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. 15. August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Biostatistics Unit, School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain. 16. August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Brain Ischemia and Neurodegeneration, Institute for Biomedical Research of Barcelona, Spanish Research Council, Barcelona, Spain.
Abstract
INTRODUCTION:Uric acid is an antioxidant with neuroprotective effects in experimental models of stroke. We assessed whether uric acid therapy would improve functional outcomes at 90 days in patients with acute ischaemic stroke. METHODS: URICO-ICTUS was a randomised, double-blind, placebo-controlled, phase 2b/3 trial that recruited patients with acute ischaemic stroke admitted to ten Spanish stroke centres. Patients were included if they were aged 18 years or older, had received alteplase within 4·5 h of symptom onset, and had an eligible National Institutes of Health Stroke Scale (NIHSS) score (>6 and ≤25) and premorbid (assessed by anamnesis) modified Rankin Scale (mRS) score (≤2). Patients were randomly allocated (1:1) to receive uric acid 1000 mg or placebo (both infused intravenously in 90 min during the infusion of alteplase), stratified by centre and baseline stroke severity. The primary outcome was the proportion of patients with excellent outcome (ie, an mRS score of 0-1, or 2 if premorbid score was 2) at 90 days, analysed in the target population (all randomly assigned patients who had been correctly diagnosed with ischaemic stroke and had begun study medication). The study is registered with ClinicalTrials.gov, number NCT00860366. FINDINGS:Between July 1, 2011, and April 30, 2013, we randomly assigned 421 patients, of whom 411 (98%) were included in the target population (211 receiveduric acid and 200 received placebo). 83 (39%) patients who received uric acidand 66 (33%) patients who received placebo had an excellent outcome (adjusted risk ratio 1·23 [95% CI 0·96-1·56]; p=0·099). No clinically relevant or statistically significant differences were reported between groups with respect to death (28 [13%] patients who received uric acid vs 31 [16%] who received placebo), symptomatic intracerebral haemorrhage (nine [4%] vs six [3%]), and gouty arthritis (one [<1%] vs four [2%]). 516 adverse events occurred in the uric acid group and 532 in the placebo group, of which 61 (12%) and 67 (13%), respectively, were serious adverse events (p=0·703). INTERPRETATION: The addition of uric acid to thrombolytic therapy did not increase the proportion of patients who achieved excellent outcome after stroke compared with placebo, but it did not lead to any safety concerns. FUNDING: Institute of Health Carlos III of the Spanish Ministry of Health and Fundación Doctor Melchor Colet.
RCT Entities:
INTRODUCTION:Uric acid is an antioxidant with neuroprotective effects in experimental models of stroke. We assessed whether uric acid therapy would improve functional outcomes at 90 days in patients with acute ischaemic stroke. METHODS: URICO-ICTUS was a randomised, double-blind, placebo-controlled, phase 2b/3 trial that recruited patients with acute ischaemic stroke admitted to ten Spanish stroke centres. Patients were included if they were aged 18 years or older, had received alteplase within 4·5 h of symptom onset, and had an eligible National Institutes of Health Stroke Scale (NIHSS) score (>6 and ≤25) and premorbid (assessed by anamnesis) modified Rankin Scale (mRS) score (≤2). Patients were randomly allocated (1:1) to receive uric acid 1000 mg or placebo (both infused intravenously in 90 min during the infusion of alteplase), stratified by centre and baseline stroke severity. The primary outcome was the proportion of patients with excellent outcome (ie, an mRS score of 0-1, or 2 if premorbid score was 2) at 90 days, analysed in the target population (all randomly assigned patients who had been correctly diagnosed with ischaemic stroke and had begun study medication). The study is registered with ClinicalTrials.gov, number NCT00860366. FINDINGS: Between July 1, 2011, and April 30, 2013, we randomly assigned 421 patients, of whom 411 (98%) were included in the target population (211 received uric acid and 200 received placebo). 83 (39%) patients who received uric acid and 66 (33%) patients who received placebo had an excellent outcome (adjusted risk ratio 1·23 [95% CI 0·96-1·56]; p=0·099). No clinically relevant or statistically significant differences were reported between groups with respect to death (28 [13%] patients who received uric acid vs 31 [16%] who received placebo), symptomatic intracerebral haemorrhage (nine [4%] vs six [3%]), and gouty arthritis (one [<1%] vs four [2%]). 516 adverse events occurred in the uric acid group and 532 in the placebo group, of which 61 (12%) and 67 (13%), respectively, were serious adverse events (p=0·703). INTERPRETATION: The addition of uric acid to thrombolytic therapy did not increase the proportion of patients who achieved excellent outcome after stroke compared with placebo, but it did not lead to any safety concerns. FUNDING: Institute of Health Carlos III of the Spanish Ministry of Health and Fundación Doctor Melchor Colet.
Authors: Roy G Cutler; Simonetta Camandola; Neil H Feldman; Jeong Seon Yoon; James B Haran; Sandro Arguelles; Mark P Mattson Journal: Neurobiol Aging Date: 2018-12-12 Impact factor: 4.673
Authors: Alicia Aliena-Valero; Júlia Baixauli-Martín; María Castelló-Ruiz; Germán Torregrosa; David Hervás; Juan B Salom Journal: J Cereb Blood Flow Metab Date: 2020-11-19 Impact factor: 6.200
Authors: Dan Lindholm; Johanna Mäkelä; Valentina Di Liberto; Giuseppa Mudò; Natale Belluardo; Ove Eriksson; Mart Saarma Journal: Cell Mol Life Sci Date: 2015-11-30 Impact factor: 9.261
Authors: Dae-Hyun Kim; Jeffrey L Saver; Sidney Starkman; David S Liebeskind; Latisha K Ali; Lucas Restrepo; May Kim-Tenser; Miguel Valdes-Sueiras; Marc Eckstein; Frank Pratt; Samuel Stratton; Scott Hamilton; Robin Conwit; Nerses Sanossian Journal: Stroke Date: 2015-12-10 Impact factor: 7.914